Milea Timbergen

194 Table 1. (continued) Total n=329 Kim et al. (n = 49) 43 Salas et al. (n = 39) 49 Nishida et al. 42 (n = 3) Mullen et al. 20 (n = 63) Mussi et al. 41 (n = 17) Van Broekhoven et al. 22 (n = 47) Colombo et al. 23 (n = 111) Tumour size in mm b ≤37 mm 82 (24.9%) 7 (14.3%) 6 (15.4%) 0 11 (17.5%) 9 (52.9%) 29 (61.7%) 20 (18%) >37≤55 mm 82 (24.9%) 11 (22.4%) 10 (25.6) 3 (100%) 15 (23.8%) 4 (23.5%) 10 (21.3%) 29 (26.1%) >55≤90 mm 89 (27.1%) 14 (28.6%) 12 (30.8%) 0 21 (33.3%) 1 (5.9%) 7 (14.9%) 34 (30.6%) > 90 mm 69 (21%) 17 (34.7%) 9 (23.1%) 0 16 (25.4%) 3 (17.6%) 1 (2.1%) 23 (20.7%) Unknown 7 (2.1 %) 0 2 (5.1%) 0 0 0 0 5 (4.5%) Resection margin status R0 185 (56.2%) 26 (53.1%) 20 (50%) 0 26 (41.3%) 16 (94.1%) 27 (57.4%) 70 (63.1%) R1 126 (38.3%) 16 (32.7%) 17 (45%) 3 (100%) 37 (58.7%) 0 15 (31.9%) 38 (34.2%) Unknown 18 (5.5%) 7 (14.3%) 2 (5%) 0 0 1 (5.9%) 5 (10.6%) 3 (2.7%) Mutation type S45F 66 (20.1%) 6 (12.2%) 9 (23.1%) 0 14 (22.2%) 1 (5.9%) 10 (21.3%) 26 (23.4%) T41A 154 (46.8%) 29 (59.2%) 17 (43.6%) 3 (100%) 31 (49.2%) 6 (35.3%) 23 (48.9%) 45 (40.5%) S45P 24 (7.3%) 3 (6.1%) 7 (17.9%) 0 1 (1.6%) 1 (5.9%) 3 (6.4%) 9 (8.1%) WT 85 (25.8%) 11 (22.4%) 6 (15.4%) 0 17 (27%) 9 (52.9% 11 (23.4%) 31 (27.9%) Recurrence Yes 83 (25.2%) 16 (32.7%) 8 (20.5%) 0 15 (23.8%) 1 (5.9%) 9 (19.1%) 34 (30.6%) No 246 (74.8%) 33 (67.3%) 31 (79.5%) 3 (100%) 48 (76.2%) 16 (94.1%) 38 (80.9%) 77 (69.4%) EA NS, extra-abdominal not specified; SD, standard deviation; WT, wild-type; Missing values in tumour size (n = 7) are not included in mean and median tumour size calculation a due to a limited number of patients this value represents the minimum and maximum values b categories based on quartiles 7